JC35 (Medicine) - Obesity Flashcards

1
Q

Clinical methods to quantify obesity

A

Weight

BMI

Waist to hip ratio

Skin fold thickness

Waist circumference

Total body fat estimate

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

Cut-off points of BMI

A

Underweight: <18.5

Acceptable risk: 18.5-23

Increased risk: 23-27.5

High risk: >27.5

Or

Underweight: <18.5

Normal: 18.5-23

Overweight: 23-25

Obese: >25

Obese Class I: 25-30

Obese Class II: >30

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

Measures of fat distribution

Function

A

Assessed clinically by:

Waist:hip ratio (WHR): defined as ≥0.95 (M) or ≥0.80 (F)

Waist circumference: Chinese: ≥90cm (M), ≥80cm (F)

Function: Measure Central (abdominal) obesity: intra-abdominal fat accumulation
→ Stronger relationship with metabolic syndrome, T2DM, cardiovascular diseases

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

Definition of metabolic syndrome (NCEP ATP)

A

NCEP ATP III (2005) definition of
metabolic syndrome (syndrome X):
≥3 out of 5 of
(1) Central obesity: waist circumference >40 inches (M), >35 inches (F)

(2) Insulin resistance or diabetes: fasting glucose ≥5.5mmol/L or on treatment
(3) Hypertriglyceridaemia: >1.7mmol/L
(4) Low HDL-C: <1.034mmol/L (M), <1.293mmol/L (F) or on treatment
(5) Hypertension: >130 SBP or >85 DBP or on treatment

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

Cardiovascular and Metabolic diseases linked to obesity

A

□ CVS: HTN, CAD, stroke
□ Metabolic: T2DM, dyslipidemia, insulin resistance, polycystic ovary disease

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

GI and Resp. and Neurological diseases linked to obesity

A

□ GI: hiatus hernia, gallstones, colorectal cancer, non-alcoholic fatty liver disease

□ Respiratory: obesity-hypoventilation syndrome, dyspnoea, OSA

□ Neurological: nerve entrapment, sciatica

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

Breast, Genitourinary, Orthopaedic and Psychological diseases linked to Obesity

A

□ Breast: breast cancer, gynaecomastia
□ Genitourinary: stress incontinence, ↓fertility (due to PCOS), pregnancy complications
□ Orthopaedics: OA of weight-bearing joints
□ Psychological: poor self-esteem, depression

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

Causes of primary obesity

A
  1. Mismatch between energy intake and energy expenditure
  2. Multiple influences including genetic, environmental and behavioural factors

Genetic influences:

  • Generally polygenic
  • ~33% hereditability

Environmental factors:

  • Food intake and dietary fat content
  • Sedentary lifestyle
  • Socio-economic status (inverse relationship)
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

Causes of secondary obesity (medical causes)

A

Medical conditions:

□ Hypothyroidism (commonest)
□ Cushing’s syndrome
□ Hypogonadism in male
□ Polycystic ovary syndrome in female
□ GH deficiency
□ Hypothalamic tumours

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

Causes of secondary obesity (drug causes)

A

Antidepressants

Antipsychotics

Diabetic medication

Glucocorticoids

Anticonvulsants

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

Physiological control of energy balance and adiposity

A

Peripheral signals:

Long-term signals of energy stores + short-term fluctuations in food intake released from adipose tissues and gut endocrine system > Release mixture of Insulin, CCK, GLP-1, Leptin, Ghrelin…etc

Integrated in hypothalamus and brainstem
→ modulate neuropeptide release, autonomic nervous system
→ changes in appetite, behaviour, energy expenditure
→ stable weight maintained

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

Function of hypothalamus in weight control

Mechanism

A

Hypothalamus

  1. Function: integrates neural, hormonal and nutrient messages from body
    send signals to higher centres
  2. Mediate feeling of hunger or satiety
  3. Cause changes in appetite, behaviour, energy expenditure

Mechanisms:

  1. Variety of hypothalamic neurotransmitters controls food intake and thermogenesis
    - ↑intake: opioid, GHRH, neuropeptide Y
    - ↓intake: 5HT, GLP-1, DA, cholecystokinin
  2. Acts via ANS and pituitary hormones to control energy expenditure
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

Neurotransmitters released by hypothalamus that affect food intake

A

Increase food intake:

\Opioids. Growth-hormone releasing hormone, Neuropeptide Y

Inhibit food intake:

Serotonin, Glucagon-like peptide 1, CCK, Dopamine, Corticotrophin-releasing factor

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

Function of adipose tissue in weight control

Mechanism

A

Adipose tissue - active endocrine and secretory organ

  1. Adipokines:

Examples: adiponectin, TNF-α, IL-1β, IL-6, IL-8, IL-1

Variety of effect on body functions and energy balance

  1. Leptin: peptide hormone made by adipocytes

Normal: acts on hypothalamus to lower food intake + increase energy expenditure

High fat: Increase leptin level and concentration with increase fat mass >> hypothalamus gain partial resistance to leptin

  1. Release fatty acid and other lipid moieties
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

Pathophysiology of weight retention

A

Gut endocrine and adipose tissue >> hormonal and autonomic signal to hypothalamus

Sustained release of stimulating hormones and decrease in appetite-suppression hormones >> hypothalamic resistance/ partial resistance

>> adaptation to defend against weight loss

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

Aims of obesity management

A
  1. Weight reduction with maintenance of weight loss
  2. Modify concurrent risk factors for mortality and morbidity (smoking, DM, HTN, HL…etc)

5-10% weight loss required for therapeutic benefits

17
Q

Strategies for weight reduction

A

Lifestyle modification - diet therapy + exercise

Drug therapy

Surgery

18
Q

Outline lifestyle modifications for weight reduction

A

Dietary therapy:
Low-calorie diet (LCD): ≥800kcal/d (typically 800-1500)
Very low-calorie diet (VLCD): <800kcal/d

Optimal weight loss = ~0.5kg/week (600kcal/day deficit)

Physical activity:
□ Combination with dietary modification important for initial weight loss and long-term weight
maintenance
□ Target: Increase until energy expenditure of 1000-1500kcal/w

Behavioral treatment: Increase compliance:

Relapse prevention therapy, Problem-solving therapy, Social support, Telephone contact, Structured meal plans…etc

19
Q

Compare Low-calorie diet and Very low calorie diet

  • Calories limit
  • Effectiveness
A

Low-calorie diet (LCD): ≥800kcal/d (typically 800-1500)
Very low-calorie diet (VLCD): <800kcal/d

VLCD:

  • Faster rate of weight reduction in first 2-3mo but not superior in maintenance of weight loss after 1y
  • Should only be used under medical supervision
  • Faster rate of weight loss asso. with concurrent fat and lean muscle loss

Treatment effects:
Effective in promoting significant weight loss (max 4-7%)
Long-term weight loss in most trials ~2-6kg

20
Q

Drug therapy for weight loss

  • All options
  • Banned options
  • Indications
A

Indication:

  • Obesity pose medical risk: BMI >30 or BMI = 27-29 + comorbidities
  • NOT responded to traditional conservative management

Options:

  1. Orlistat (Xenical) - GI lipase inhibitor
  2. Phentermine/ Topiramate (Qsymia) - noradrenaline + anti-epileptic
  3. Bupoprion/ Naltrexone (Contrave) - dopamine reuptake inhibitor + opioid agonist
  4. Liraglutide - GLP-1 receptor agonist

Withdrawn options:

Serotonergic agents (Sibutramine, Lorcaserin), Endocannabinoid receptor antagonists (Rimonabant)

21
Q

Orlistat

  • MoA
  • Effect
  • S/E
A

MoA: GI lipase inhibitor → ↓absorption of dietary fat

Effect: can ↓dietary fat by 30% with dose of 12mg TDS

S/E:
→ GI: GI upset, steatorrhoea, ↓fat soluble vitamin absorption, fecal urgency, oily spotting
→ Systemic: minimal (minimal systemic absorption)

22
Q

Phentermine/topiramate (Qsymia)

  • MoA
  • S/E
A

MoA:
Phentermine: ↑noradrenaline release + possibly blockade of NA reuptake → anorexia
Topiramate: anti-epileptic, migraine prophylaxis (mechanism unknown)

S/E:

teratogenicity, slight ↑HR, psychiatric/cognitive S/E, metabolic acidosis

23
Q

Bupoprion/Naltrexone (Contrave)

  • MoA
  • S/E
    *
A

MoA: ↓appetite and cravings for food
Bupoprion: dopamine/noradrenaline reuptake inhibitor, usually as antidepressant and aid
smoking cessation
Naltrexone: opioid antagonist, usually for treating alcohol and opioid dependence

S/E: nausea, constipation, headache, vomiting, dizziness, insomnia, dry mouth and diarrhoea

→ Also monitor for mood changes, suicidal thoughts and actions

24
Q

Liraglutide (Saxenda)

  • MoA
  • Administration
  • S/E
A

Liraglutide (Saxenda):
MoA: GLP-1 receptor agonist

  1. ↑glucose-stimulated insulin secretion,
  2. ↓glucagon secretion,
  3. delayed gastric emptying,
  4. ↑satiety by direct central effect on hypothalamus

RoA: subcutaneous injections

S/E: mainly GI upset

25
Q

Surgery for obesity

  • Indications
  • Types
  • All options
A

Indications:

  • BMI ≥40 kg/m2 without comorbidity
  • BMI ≥35 kg/m2 with comorbidity, eg. DM, respiratory insufficiency
  • Refractory to medical treatments

Types:

□ Restrictive: ↓size of reservoir for intake
□ Malabsorptive: ↓efficacy of absorption

Restrictive bariatric surgery:

  • Vertical sleeve gastrectomy (VSG)
  • Adjustable gastric banding (AGB)
  • Roux-en-Y gastric bypass (RYGB)
  • Biliopancreatic Diversion with duodenal switch (BPD-DS)

Malabsorptive options:

  • Small bowel bypass surgery
  • Bioenterics intragastric balloon
26
Q

Describe Roux-en-Y gastric bypass

A

Stomach stapled → formation of small gastric pouch
Roux-en-Y anastomosis to allow gastric, pancreatic, biliary and duodenal secretions to enter distal intestine

27
Q

Describe Vertical sleeve gastrectomy (VSG)

A

Laparoscopic excision of greater curvature by staples
creation of a new 150mL banana-shaped gastric pouch
Allow restriction of amount of food intake without any small bowel bypass and
malabsorption

More effective than AGB and comparable to RYGB

28
Q

Describe Adjustable gastric banding

Pros and Cons

A

Small inflatable belt placed around upper portion of stomach
induce early satiety → restrict amount of food consumed
Tightness of banding can be adjusted by saline infusion
allow gradual deflation after weight loss

Pros: least invasive form → ↓mortality, ↓complications
Cons: ↑relapse rate and ↓weight loss

29
Q

Describe Bioenterics intragastric ballon

A

□ Non-surgical procedure: balloon placed inside stomach by endoscope → acts as bezoar
to partially fill stomach → induce early satiety
□ Reversible, usually removed after 6-9mo
□ Considered a type of behavioural therapy to induce changes in eating habit

30
Q

Complications of ABG surgery

A

Band slippage

Leakage

Erosion

31
Q

Complications of bypass surgery

A

Anastomotic strictures

Marginal ulcers

Bowel obstruction

32
Q

Complications of Roux-en-Y surgery

A

Micronutrient and Macronutrient deficiency

  • Iron deficiency**
  • Calcium
  • Vitamin B12
  • Vitamin D
  • Fat-soluble vitamin (A,D,E,K)
  • Protein
33
Q

Compare efficacy of bariatric surgeries: Gastric bypass, Adjustable gastric banding, Sleeve gastrectomy

A

Gastric bypass: Most effective in weight loss, more complications

Adjustable gastric banding: Reoperation rate higher, Least weight loss, Lower mortality and overall complication rate

Sleeve gastrectomy: Similar effectiveness as gastric bypass

34
Q

Effects of bariatric surgery

A
  1. Long-term weight loss, superior to medical Tx
  2. Improve metabolic diseases
  3. Reduce CVD risks
  4. Improve morbidity and mortality